Maxygen (MAXY)
Maxygen Capital Expenditures: 0.022M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MAXY Capital Expenditures Rankings
| Overall | 76th percentile | 1043 of 4457 |
| Sector | 78th percentile | 183 of 850 in Services |
| Industry | 66th percentile | 4 of 12 in Research Services |
MAXY Capital Expenditures Range, Past 5 Years
| Minimum | 0.00 | Mar 2010 |
| Maximum | 0.593M | Dec 2007 |
| Average | 0.1329M |
About Capex
Capital expenditures are a line item from a company's statement of cash flows (click "Learn More" below for details).
Capex (short for capital expenditures) are incurred when a business spends money to purchase fixed assets or to add value to an existing fixed asset. In accounting, a capital expenditures are added to an asset account, thus increasing the value of the asset.
Examples of capital expenditures include the purchase of a new manufacturing plant, investment in server farms for tech companies, or other purchases of assets expected to help the company earn profits in the future.
Unlike other investments like research and development and marketing spending, capital expenditures are not immediately expensed. Rather, property, plant and equipment acquired using capital expenditures are usually expensed over time through the use of depreciation.
Learn More
You may also be interested in these MAXY related companies
MAXY News
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
$MAXY forms bullish "Continuation Wedge" chart pattern. http://stks.co/3OAl
about 43 days ago by RecogniaEvents
about 43 days ago by RecogniaEvents
$MAXY http://stks.co/29DH vol laden nr7 friday w/ pos hard sell below $5.4
about 122 days ago by traderdigs
about 122 days ago by traderdigs
Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome
Nov 09, 4:30PM Business Wire
Nov 09, 4:30PM Business Wire
$MAXY set to rally after breaking out of long consolidation rectangle. Looks to close the December 2010 gap at $6.80
about 232 days ago by checkthetechs
about 232 days ago by checkthetechs
Maxygen announces final rejection of '804 patent in inter partes reexamination
Oct 10, 5:17PM FlyOnTheWall
Oct 10, 5:17PM FlyOnTheWall
Maxygen Announces Final Rejection of All Claims of Amgen ‘804 Patent in Inter Partes Reexamination Proceeding
Oct 10, 5:00PM Business Wire
Oct 10, 5:00PM Business Wire
Some Swings and Scalps for Today: $RCKB $IPAS $MAXY $DGII http://stk.ly/keEf56
about 349 days ago by SharePlanner
about 349 days ago by SharePlanner
=> $MAXY $5.23 LEE KENNETH B JR director P 3,000 @ $5.23 amnt $15,690 proc'd $0 6/1/2011
about 364 days ago by canarionyc
about 364 days ago by canarionyc
$MAXY--Director purchased 20,000 shares at $5.16. Last trade is $5.08. Nice float, decent avg volume. Do your own research.
about 374 days ago by MicroInsider
about 374 days ago by MicroInsider
$MAXY $5.08 STEIN ISAAC director P 20,000 @ $5.16 amnt $103,200 proc'd ($1,600) 5/19/2011
about 376 days ago by canarionyc
about 376 days ago by canarionyc
$MAXY tries for radiation exposure BARDA award w/ MAXY-34: http://stk.ly/jd0fhC Didn't a Canadian licensee already fail with this attempt?
about 392 days ago by BioDueDiligence
about 392 days ago by BioDueDiligence
$MAXY http://chart.ly/xbp2y4t Spec biotech showing tight weekly closes after big move; like to see this - good support
about 420 days ago by Kenshreve
about 420 days ago by Kenshreve
Astellas exercises option to buy out $MAXY JV for 76m http://stk.ly/egeX5B Nice deal, but makes the 20m deal w/ $CDXS look even worse
about 441 days ago by BioDueDiligence
about 441 days ago by BioDueDiligence
$MAXY 4q2010 results: http://stk.ly/dQTWE9 Does this structure and strategy make sense to anyone besides the 5 guys still getting paychecks?
about 449 days ago by BioDueDiligence
about 449 days ago by BioDueDiligence
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MAXY | 5.81 | -0.06 | -1.02% | 163.01M |
| MAV | 15.16 | +0.00 | +0.00% | |
| MATW | 29.98 | -0.49 | -1.61% | 864.43M |
| MATR | 6.93 | -0.06 | -0.86% | 117.29M |
| MAT | 31.17 | -0.34 | -1.08% | 10.68B |
| MASC | 8.05 | -0.05 | -0.62% | 85.37M |
| MAS | 12.36 | -0.64 | -4.92% | 4.645B |
| MARPS | 23.24 | +0.74 | +3.29% | 45.00M |
| MAR | 38.29 | -0.85 | -2.17% | 13.07B |
| MAPP | 11.27 | -0.33 | -2.84% | 353.80M |
